ClinicalTrials.gg
CompletedNCT05755620Updated Nov 19, 2026Results posted

A Study to Evaluate the Safety and Immunogenicity of a Single Dose of H1ssF-3928 mRNA-LNP in Healthy Adults

A Phase 1 interventional study of Influenza Virus Quadrivalent Inactivated Vaccine and Sodium Chloride, 0.9% in Influenza, sponsored by National Institute of Allergy and Infectious Diseases (NIAID). Completed at 1 site in United States. Open to participants aged 18 Years to 49 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by National Institute of Allergy and Infectious Diseases (NIAID) · Phase 1, Interventional, and Prevention

How we know

Updated Nov 19, 2026Results postedPrimary outcomes revised+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
50
Allocation
Non-randomized
Ages
18 Years to 49 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 186 studies in Influenza, Human by National Institute of Allergy and Infectious Diseases (NIAID) — 11 open to participants now, 12 under way, none of them phase 3. Influenza, Human · National Institute of Allergy and Infectious Diseases (NIAID).

Enrollment
107th of 166
50 · median 83
Started
2023
with 4 others
Phase 1
77 of 186
5 open now
Registered
175th of 186
by date

Among the 186 studies in Influenza, Human by National Institute of Allergy and Infectious Diseases (NIAID), this one is the 107th largest by enrollment of the 166 interventional ones that give a count, is one of 5 that started in 2023, is one of 77 in phase 1, and was the 175th registered.

Influenza, Human

2,361 studies on the registry are indexed under Influenza, Human; 186 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

11 of the 186 studies in Influenza, Human by National Institute of Allergy and Infectious Diseases (NIAID) are open now, in 1 country. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Who these studies take

Of the 124 Influenza, Human studies recruiting now, 67 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 69 take healthy volunteers.

This study: 18 Years to 49 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 186 studies in Influenza, Human by National Institute of Allergy and Infectious Diseases (NIAID), or all of them as a file.
02

Study summary

This is a Phase 1, single-site, open-label, comparator-controlled dose escalating study of an intramuscularly (IM) administered mRNA-LNP vaccine encoding for (Vaccine Research Center) VRC H1ssF 3928 of up to 50 healthy adult volunteers aged 18 to 49 years, inclusive. This study is designed to assess the safety and immunogenicity of one dose of H1ssF 3928 mRNA Vaccine. Eligible participants will be sequentially enrolled into dosing groups (10 mcg, 25 mcg, and 50 mcg, selected optimal dose) to receive the H1ssF 3928 mRNA Vaccine at the specified dose. A separate group of 10 participants will receive licensed quadrivalent influenza vaccine (IIV4). Subjects receiving IIV4 will be followed for safety but only their immune responses will be compared to those of participants receiving H1ssF 3928 mRNA Vaccine. Dosing of H1ssF 3928 mRNA Vaccine will commence at the lowest dose (10 mcg) and only escalate to the next highest dose if safety concerns are not identified. Up to ten subjects will be enrolled per dosing cohort. Reactogenicity and adverse event (AE) information through Day 7 and clinical laboratory results through Day 8 from the first three dosing groups will guide the selection of an optimal dose group to include 10 subjects who will receive the optimal dose of mRNA-LNP. The primary objective of this study is to assess the safety of a single dose of VRC H1ssF 3928 mRNA-LNP vaccine administered IM in healthy adults, 18-49 yrs, at doses of 10 mcg, 25 mcg, and 50 mcg.

Read the detailed description

This is a Phase 1, single-site, open-label, comparator-controlled dose escalating study of an intramuscularly (IM) administered mRNA-LNP vaccine encoding for (Vaccine Research Center) VRC H1ssF 3928 of up to 50 healthy adult volunteers aged 18 to 49 years, inclusive. This study is designed to assess the safety and immunogenicity of one dose of H1ssF 3928 mRNA Vaccine. Eligible participants will be sequentially enrolled into dosing groups (10 mcg, 25 mcg, and 50 mcg, selected optimal dose) to receive the H1ssF 3928 mRNA Vaccine at the specified dose. A separate group of 10 participants will receive licensed quadrivalent influenza vaccine (IIV4). Subjects receiving IIV4 will be followed for safety but only their immune responses will be compared to those of participants receiving H1ssF 3928 mRNA Vaccine. Dosing of H1ssF 3928 mRNA Vaccine will commence at the lowest dose (10 mcg) and only escalate to the next highest dose if safety concerns are not identified. For each VRC H1ssF 3928 mRNA-LNP (Lipid Nanoparticle) dosing group, the first two subjects enrolled will be considered the sentinel subgroup. After the two subjects in the Low Dose sentinel subgroup are enrolled and given their vaccination, enrollment will then be stopped pending a review of the reactogenicity and safety data collected through Day 3 for both subjects. Approval by the reviewing group will allow for continued enrollment of the remaining Low Dose Group subjects to complete enrollment of 10 participants. After Low Dose Group enrollment is completed, enrollment will be stopped pending an Safety Review Committee (SRC) review of the reactogenicity and adverse event (AE) information through Day 7 and clinical laboratory results through Day 8 for all Low Dose Group subjects. Approval will allow dose escalation and initiation of enrollment of the Medium Dose Group sentinel subgroup. After the two subjects in the Medium Dose sentinel subgroup are enrolled and given their vaccination, enrollment will then be stopped pending a safety review of the sentinel subgroup as specified for the Low Dose Group. Approval will allow for continued enrollment of Medium Dose Group subjects to complete enrollment of 10 participants. After the Medium Dose Group enrollment is completed, enrollment will be stopped pending an SRC review of the reactogenicity and adverse event information through Day 7 and clinical laboratory results through Day 8 for all Medium Dose Group subjects. Approval will allow dose escalation and initiation of enrollment of the High Dose Group sentinel subgroup. After the two subjects in the High Dose sentinel subgroup are enrolled and given their vaccination, enrollment will then be stopped pending a safety review of the sentinel subgroup as specified for the Low and Medium Dose Groups. Approval will allow for continued enrollment of High Dose Group subjects to complete enrollment of 10 participants. After the High Dose Group enrollment is completed, enrollment will be stopped pending an SRC review of the reactogenicity and adverse event information through Day 7 visit and clinical laboratory results through Day 8 for all High Dose Group subjects. Reactogenicity and AE information through Day 7 and clinical laboratory results through Day 8 from the first three dosing groups will guide the selection of an optimal dose group to include an additional 10 subjects who will receive the optimal dose of mRNA-LNP. The primary objective of this study is to assess the safety of a single dose of VRC H1ssF 3928 mRNA-LNP vaccine administered IM in healthy adults, 18-49 yrs, at doses of 10 mcg, 25 mcg, and 50 mcg. The secondary objective of this study is to assess serum antibody responses to a single dose of VRC H1ssF 3928 mRNA-LNP vaccine administered IM in healthy adults at doses of 10 mcg, 25 mcg, and 50 mcg in comparison to a standard dose of IIV4.

03

Conditions studied

  • Influenza

Browse trials for

Keywords

  • Comparator-Controlled
  • Dose-Escalation
  • H1ssF-3928
  • Healthy Adults
  • mRNA-LNP
  • Phase 1
04

Who can participate

Ages eligible
18 Years to 49 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provide written prior to initiation of any study procedure.
  2. Are able to understand and comply with planned study procedures and be available for all study visits.
  3. Are males or non-pregnant, non-breastfeeding females, 18 to 49 years of age, inclusive at time of screening and enrollment.
  4. Must agree to collection of venous blood and nasal absorption specimens per protocol and enrollment in DMID Protocol No. 19-0025 biorepository protocol for secondary research and use of residual biologic specimens.
  5. Are in good health* and do not have medical, psychiatric, chronic or intermittent health conditions including those listed in Exclusion Criteria (Section 1).

    *As determined by medical history, medication use, and physical examination to evaluate ongoing chronic medical or psychiatric diagnoses or conditions, defined as those that have been present for at least 90 days, which would not affect the assessment of the safety of subjects or the immunogenicity of study vaccinations. These medical diagnoses or conditions should be stable for the last 60 days (no hospitalizations, emergency room [ER] or urgent care for condition [excluding musculoskeletal conditions], or invasive medical procedure and no adverse symptoms that need medical intervention such as medication change/supplemental oxygen). This includes no change in chronic prescription medication, dose or in the 60 days prior to enrollment. Any prescription change that is due to change of health care provider, insurance company, etc., or that is done for financial reasons, as long as in the same class of medication, will not be considered a deviation of this inclusion criterion. Subjects may be on chronic or as needed (prn) medications if, in the opinion of the site PI or appropriate sub-investigator, they pose no additional risk to subject safety or assessment of reactogenicity and immunogenicity and do not indicate a worsening or treatment of continued symptoms of medical diagnosis or condition. Note: Low dose topical, as outlined in the Subject Exclusion Criteria (see Section 1) as well as herbals, vitamins and supplements are permitted.

  6. Does not have an ongoing symptomatic condition* for which subject has had or has ongoing medical investigations but has not yet received a diagnosis or treatment plan.

    *e.g., ongoing fatigue without a diagnosis for symptom.

  7. Pulse is 50 to 100 beats per minute, inclusive.
  8. Systolic blood pressure is 90 to 140 mmHg, inclusive.
  9. Diastolic blood pressure is 55 to 90 mmHg, inclusive.
  10. (BMI) of 18 kilograms/square meter (kg/m\^2) (inclusive) to \<35 kg/m\^2 at screening
  11. Women of * must agree to use or have practiced true abstinence** or use at least 1 acceptable primary form of .***

    *Not of child bearing potential - females (defined as having a history of amenorrhea for at least one year) or a documented status as being surgically sterile (hysterectomy, bilateral oophorectomy, salpingectomy, or Essure placement with history of documented radiological confirmation test at least 90 days after the procedure).

    **True abstinence is 100% of time no sexual intercourse (male's penis enters the female's vagina). (Periodic abstinence [e.g. calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception).

    • Acceptable forms of primary contraception include monogamous relationship with a vasectomized partner who has been vasectomized for 180 days or more prior to the subject receiving the study product, tubal ligation, intrauterine devices, birth control pills, and injectable/implantable/insertable hormonal birth control products.
    • Must use at least one acceptable primary form of contraception or true abstinence for at least 30 days prior to receipt of study product and at least one acceptable primary form of contraception or true abstinence for at least 30 days following receipt of study product.
  12. Women of childbearing potential must have a negative serum HCG pregnancy test at screening and a negative urine HCG pregnancy test within 24 hours prior to the study vaccination.
  13. Male participants receiving VRC H1ssF_3928 mRNA-LNP must agree to refrain from donating sperm and to use contraception until Day 60 after vaccination.*

    • Acceptable contraception includes abstinence from intercourse with a female of childbearing potential or use of a male condom when engaging in any activity that allows for passage of ejaculate to a female during the intervention period for at least 60 days after study vaccination.
    • Males in the immunogenicity comparator group do not have to refrain from sperm donation or abstain from intercourse or agree to use a male condom for purposes of this study.
  14. Must have received at least one licensed seasonal influenza vaccine within the previous 5 seasons.

Exclusion criteria

Exclusion Criteria:

  1. Have an acute illness* or fever (body temperature > / = 38.0 degrees Celsius/100.4 degrees Fahrenheit), as determined by the site Principal Investigator (PI) or appropriate sub-investigator, within 72 hours prior to study vaccination.

    *An acute illness which is nearly resolved with only minor residual symptoms remaining is allowable if, in the opinion of the site PI or appropriate sub-investigator, the residual symptoms will not interfere with the ability to assess safety parameters as required by the protocol.

  2. Have any medical disease or condition that, in the opinion of the site PI or appropriate sub-investigator, is a to study participation.*

    * Including acute, subacute, intermittent or chronic medical disease or condition that would place the subject at an unacceptable risk of injury, render the subject unable to meet the requirements of the protocol, or may interfere with the evaluation of responses or the subject's successful completion of this trial.

  3. Has a screening laboratory* > Grade 1.

    *White blood cell count, , absolute lymphocyte count, , count, (PT), activated partial thromboplastin time (APTT), fibrinogen, creatinine, (ALT), aspartate aminotransferase (AST), alkaline phosphatase, total , lipase.

  4. Has a positive urine toxicology screen (i.e., non-prescribed amphetamines, cocaine, and opiates).
  5. (ECG) is deemed to be by the PI or appropriate sub-investigator.
  6. Total iron binding capacity, iron, ferritin and troponin (hsTnl) outside the laboratory normal range at screening.
  7. Have any known or suspected condition, acquired or congenital, or conditions as determined by history and/or physical examination.
  8. Have immunosuppression as result of treatment including a recent history (within 6 months prior to administration of study vaccine) or use of immunosuppressive or other immune-modifying drugs.
  9. Use of anticancer chemotherapy or radiation therapy (cytotoxic) within 3 years prior to study vaccination.
  10. Have known active or recently active (12 months) neoplastic disease or a history of any hematologic . Non-melanoma, treated, skin cancers are permitted.
  11. Have known (HIV), or infection at screening.
  12. Have a positive test result for hepatitis B surface antigen, hepatitis C virus antibody, or HIV types 1 or 2 antibodies at screening.
  13. Have known chronic liver disease, including fatty liver disease.
  14. Have a known allergy or severe allergic reaction to any components of the study vaccine (including polyethylene glycol [PEG]) or the seasonal influenza vaccine (including egg protein).
  15. Have a history of a severe reaction following previous immunization with an , authorized, or approved influenza vaccine or mRNA or LNP-containing vaccine containing vaccine.
  16. Have a history of Guillain-Barré Syndrome.
  17. Have a known history of myocarditis or pericarditis.
  18. Have a history of alcohol or drug abuse within 3 years prior to study vaccination.
  19. Have any diagnosis, current or past, of schizophrenia, bipolar disease or other psychiatric diagnosis that may interfere* with subject compliance or safety evaluations.

    *As determined by the site PI or appropriate sub-investigator.

  20. Have been hospitalized for psychiatric illness, history of suicide attempt, or confinement for danger to self or others within 5 years prior to study vaccination.
  21. Have taken oral or parenteral (including intra-articular) of any dose within 30 days prior to study vaccination. Intranasal or topical (skin or eyes) corticosteroids are permitted.
  22. Have taken high-dose inhaled or nebulized corticosteroids* within 30 days prior to study vaccination.

    *High-dose defined as per age as using inhaled high-dose per reference chart in the National Heart, Lung and Blood Institute Guidelines for the Diagnosis and Management of Asthma (EPR-3) or other lists published in UPTODATE

  23. Have any significant disorder of coagulation requiring ongoing or intermittent treatment.
  24. Have received seasonal influenza vaccine within 90 days prior to enrollment or plans to receive a seasonal influenza vaccine 60 days after study vaccination.
  25. Have received any approved or authorized vaccines other than seasonal influenza vaccine within 60 days before enrollment or plans to receive an approved or authorized vaccine 60 days after study vaccination.
  26. Have a known history of documented influenza infection within the past 90 days.
  27. Have a history of receipt of an investigational H1 influenza vaccine within the past 10 years.
  28. Have a history of receipt of a ferritin-based vaccine or an investigational H5 influenza vaccine.
  29. Previous participation in DMID Protocol No. 18-0010 human influenza challenge study.
  30. Received immunoglobulin and/or any blood products (except Rho D immunoglobulin) within the 90 days prior to study vaccination.
  31. Received an experimental agent *within 60 days prior to the study vaccination or expect to receive another experimental agent during the trial-reporting period.**

    *Including vaccine, drug, biologic, device, blood product, or medication.

    **Other than from participation in this trial

  32. Are participating or plan to participate in another clinical trial with an interventional agent* that will be received during the trial-reporting period.*

    • Including licensed or unlicensed vaccine, drug, biologic, device, blood product, or medication.
    • Approximately 12 months after the first study vaccination.
  33. The subject has any abnormality or permanent body art (e.g., tattoo) that, in the opinion of the investigator or appropriate sub-investigator, would obstruct the ability to observe local reactions at the injection site.
  34. Donation of blood or blood products within 30 days prior to dosing and plans to donate within 60 days following dosing.
  35. Has had significant exposure to someone with laboratory-confirmed severe acute respiratory syndrome (SARS-CoV-2) infection or influenza in the 14 days prior to screening or during the period between screening and enrollment visit.*

    *Defined by the Centers for Disease Control and Prevention (CDC) as a close contact with someone who has COVID-19.

  36. Has had a positive SARS-CoV-2 test (home or laboratory-based) within 14 days prior to the screening visit or during the period between screening and enrollment visits.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    Arm 1, Low Dose

    10 healthy adult volunteer subjects from 18-49 years of age are split into two subgroups. The sentinel subgroup includes 2 vaccine recipients who will receive 10 mcg of the H1ssF\_3928 mRNA Vaccine, administered intramuscularly once. The sentinel subgroup is observed for 8 days to monitor any early vaccine related adverse events. After the observation period, the remaining participants will receive the same dosage, 10 mcg of the H1ssF 3928 mRNA vaccine administered intramuscularly once. N = 10

    Other: Sodium Chloride, 0.9% · Biological: VRC-FLUNPF099-00-VP (H1ssF_3928)

  • Experimental
    Arm 2, Medium Dose

    10 healthy adult volunteer subjects from 18-49 years of age are split into two subgroups. The sentinel subgroup includes 2 vaccine recipients who will receive 25 mcg of the H1ssF\_3928 mRNA Vaccine, administered intramuscularly once. The sentinel subgroup is observed for 8 days to monitor any early vaccine related adverse events. After the observation period, the remaining participants will receive the same dosage, 25 mcg of the H1ssF 3928 mRNA vaccine administered intramuscularly once. N = 10

    Other: Sodium Chloride, 0.9% · Biological: VRC-FLUNPF099-00-VP (H1ssF_3928)

  • Experimental
    Arm 3, High Dose

    Experimental: Arm 3, High Dose 10 healthy adult volunteer subjects from 18-49 years of age are split into two subgroups. The sentinel subgroup includes 2 vaccine recipients who will receive 50 mcg of the H1ssF\_3928 mRNA Vaccine, administered intramuscularly once. The sentinel subgroup is observed for 8 days to monitor any early vaccine related adverse events. After the observation period, the remaining participants will receive the same dosage, 50 mcg of the H1ssF 3928 mRNA vaccine administered intramuscularly once. The High Dose was selected as the optimal dose as it was the highest dose with no identified safety concerns by the Safety Review Committee (SRC). An additional 10 (optimal dose) participants were therefore enrolled into the High Dose group. Total N = 20

    Other: Sodium Chloride, 0.9% · Biological: VRC-FLUNPF099-00-VP (H1ssF_3928)

  • Active comparator
    Arm 4, IIV4

    10 healthy adult volunteer subjects from 18-49 years of age will receive licensed Quadrivalent Influenza Vaccine (IIV4), administered intramuscularly once. Subjects receiving IIV4 will be followed for safety, but only their immune responses will be compared to those of participants receiving H1ssF\_3928 mRNA Vaccine. N=10

    Biological: Influenza Virus Quadrivalent Inactivated Vaccine

Interventions

  • BiologicalInfluenza Virus Quadrivalent Inactivated Vaccine

    A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes and 2 influenza B subtypes.

  • OtherSodium Chloride, 0.9%

    0.9% Sodium Chloride Injection

  • BiologicalVRC-FLUNPF099-00-VP (H1ssF_3928)

    The vaccine consists of modified nucleoside messenger RNA (mRNA) encapsulated in lipid nanoparticles (LNP), comprised of four lipid components: (ALC-307 (ionizable lipid), DSPC, cholesterol, and ALC-0159 \[PEG lipid\]).

06

What researchers measure

Primary outcomes

  1. Number and Percentage of Participants Experiencing Solicited Local and Systemic Reactogenicity Adverse Events (AEs)

    Number and percentage of participants in each dose group experiencing solicited local and systemic reactogenicity adverse events, of all severity grades and by grade

    Time frame: Day of vaccination through 13 days post-vaccination

  2. Number and Percentage of Participants Experiencing Any Unsolicited AEs

    Number and percentage of participants in each dose group experiencing unsolicited adverse events (AEs), of all severity grades and by grade

    Time frame: Day of vaccination through 28 days post-vaccination

  3. Number and Percentage of Participants Experiencing Any New-onset Chronic Medical Conditions (NOCMCs)

    Number and percentage of participants in each dose group experiencing NOCMCs

    Time frame: Day of vaccination through end of study participation (approximately 365 days post-vaccination)

  4. Number and Percentage of Participants Experiencing Any Adverse Events of Special Interest (AESIs) Corresponding to Grade 2 or Greater Decrease in Lymphocyte or Neutrophil Count

    Number and percentage of participants in each dose group experiencing AESIs corresponding to Grade 2 or greater decrease in lymphocyte or neutrophil count

    Time frame: Day of vaccination through end of study participation (approximately 365 days post-vaccination)

  5. Number and Percentage of Participants Experiencing Any Influenza-like Illnesses (ILIs)

    Number and percentage of participants in each dose group experiencing ILIs

    Time frame: Day of vaccination through end of study participation (approximately 365 days post-vaccination)

  6. Number and Percentage of Participants Experiencing Any Serious Adverse Events (SAEs)

    Number and percentage of participants in each dose group experiencing SAEs

    Time frame: Day of vaccination through end of study participation (approximately 365 days post-vaccination)

  7. Number and Percentage of Participants Experiencing AESIs Corresponding to Myocarditis, Pericarditis, or Myopericarditis

    Number and percentage of participants in each dose group experiencing AESIs corresponding to myocarditis, pericarditis, or myopericarditis

    Time frame: Day of vaccination through 56 days post-vaccination

  8. Number and Percentage of Participants Experiencing Clinical Laboratory AEs

    Number and percentage of participants in each dose group experiencing clinical laboratory AEs

    Time frame: Day of vaccination through 56 days post-vaccination

Secondary outcomes

  1. Geometric Mean Titers (GMT) of Homologous H1-specific Neutralizing Antibodies in a Reporter Microneutralization Assay

    Titers for each participant are estimated as the geometric mean of technical replicate results, and the geometric mean is taken again across participants in each dose group at each time point. Results will also be stratified by prior season's receipt of seasonal influenza vaccine within each dose group. Rows are "VRC H1ssF\_3928 mRNA-LNP" and "VRC H1ssF\_3928 mRNA-LNP + Receipt of Prior Season's Influenza Vaccine"

    Time frame: Days 1 (day of vaccination), 8, 15, 29, and 57

  2. Geometric Mean Fold Rise (GMFR) of Homologous H1-specific Neutralizing Antibodies in a Reporter Microneutralization Assay

    Titers for each participant are estimated as the geometric mean of technical replicate results. Fold-rise in titers is calculated as the post-vaccination titer divided by the pre-vaccination titer. The geometric mean of fold-rises is taken again across participants in each group at each time point. Results will also be stratified by prior season's receipt of seasonal influenza vaccine within each dose group.

    Time frame: Days 8, 15, 29, and 57

  3. Geometric Mean Titers (GMT) of Homologous H1-specific Neutralizing Antibodies in a Viral Microneutralization Assay

    Titers for each participant are estimated as the geometric mean of technical replicate results, and the geometric mean is taken again across participants in each dose group at each time point. Results will also be stratified by prior season's receipt of seasonal influenza vaccine within each dose group.

    Time frame: Days 1 (day of vaccination), 8, 15, 29, and 57

  4. Geometric Mean Fold Rise (GMFR) of Homologous H1-specific Neutralizing Antibodies in a Viral Microneutralization Assay

    Titers for each participant are estimated as the geometric mean of technical replicate results. Fold-rise in titers is calculated as the post-vaccination titer divided by the pre-vaccination titer. The geometric mean of fold-rises is taken again across participants in each group at each time point. Results will also be stratified by prior season's receipt of seasonal influenza vaccine within each dose group.

    Time frame: Days 8, 15, 29, and 57

  5. Geometric Mean Titers (GMT) of Anti-stalk Serum Antibodies, Measured by Enzyme Linked Immunosorbent Assay (ELISA)

    The geometric mean of titers is taken again across participants in each dose group at each time point. Results will also be stratified by prior season's receipt of seasonal influenza vaccine within each dose group.

    Time frame: Days 1 (day of vaccination), 8, 15, 29, and 57

  6. Geometric Mean Fold Rise (GMFR) of Anti-stalk Serum Antibodies, Measured by Enzyme Linked Immunosorbent Assay (ELISA)

    Fold-rise in titers is calculated as the post-vaccination titer divided by the pre-vaccination titer. The geometric mean of fold-rises is taken again across participants in each group at each time point. Results will also be stratified by prior season's receipt of seasonal influenza vaccine within each dose group.

    Time frame: Days 8, 15, 29, and 57

07

Results

Posted Nov 19, 2026

Participant flow

Participant flow — Overall Study
MilestoneArm 1, Low DoseArm 2, Medium DoseArm 3, High DoseArm 4, IIV4
Started10102010
Completed1092010
Not completed0100
Withdrew: Lost to follow-up0100

Outcome measures

PrimaryNumber and Percentage of Participants Experiencing Solicited Local and Systemic Reactogenicity Adverse Events (AEs)

Number and percentage of participants in each dose group experiencing solicited local and systemic reactogenicity adverse events, of all severity grades and by grade

Time frame:
Day of vaccination through 13 days post-vaccination
Reported as:
Count of participants · Participants
Number and Percentage of Participants Experiencing Solicited Local and Systemic Reactogenicity Adverse Events (AEs)
ParticipantsArm 1, Low DoseArm 2, Medium DoseArm 3, High DoseAny Non-IIV4 DoseArm 4, IIV4
Any Local Solicited Event — None00114
Any Local Solicited Event — Mild668206
Any Local Solicited Event — Moderate4411190
Any Local Solicited Event — Severe00000
Any Systemic Solicited Event — None218115
Any Systemic Solicited Event — Mild778224
Any Systemic Solicited Event — Moderate11461
Any Systemic Solicited Event — Severe01010
Any Solicited Event — None00003
Any Solicited Event — Mild657186
Any Solicited Event — Moderate4413211
Any Solicited Event — Severe01010
PrimaryNumber and Percentage of Participants Experiencing Any Unsolicited AEs

Number and percentage of participants in each dose group experiencing unsolicited adverse events (AEs), of all severity grades and by grade

Time frame:
Day of vaccination through 28 days post-vaccination
Reported as:
Count of participants · Participants
Number and Percentage of Participants Experiencing Any Unsolicited AEs
ParticipantsArm 1, Low DoseArm 2, Medium DoseArm 3, High DoseAny Non-IIV4 DoseArm 4, IIV4
Any Severity249152
Mild128111
Moderate10011
Severe02130
PrimaryNumber and Percentage of Participants Experiencing Any New-onset Chronic Medical Conditions (NOCMCs)

Number and percentage of participants in each dose group experiencing NOCMCs

Time frame:
Day of vaccination through end of study participation (approximately 365 days post-vaccination)
Reported as:
Count of participants · Participants
Number and Percentage of Participants Experiencing Any New-onset Chronic Medical Conditions (NOCMCs)
ParticipantsArm 1, Low DoseArm 2, Medium DoseArm 3, High DoseAny Non-IIV4 DoseArm 4, IIV4
Number and Percentage of Participants Experiencing Any New-onset Chronic Medical Conditions (NOCMCs)10014
PrimaryNumber and Percentage of Participants Experiencing Any Adverse Events of Special Interest (AESIs) Corresponding to Grade 2 or Greater Decrease in Lymphocyte or Neutrophil Count

Number and percentage of participants in each dose group experiencing AESIs corresponding to Grade 2 or greater decrease in lymphocyte or neutrophil count

Time frame:
Day of vaccination through end of study participation (approximately 365 days post-vaccination)
Reported as:
Count of participants · Participants
Number and Percentage of Participants Experiencing Any Adverse Events of Special Interest (AESIs) Corresponding to Grade 2 or Greater Decrease in Lymphocyte or Neutrophil Count
ParticipantsArm 1, Low DoseArm 2, Medium DoseArm 3, High DoseAny Non-IIV4 DoseArm 4, IIV4
= Grade 2 decrease in lymphocyte count00000
= Grade 2 decrease in neutrophil count00000
PrimaryNumber and Percentage of Participants Experiencing Any Influenza-like Illnesses (ILIs)

Number and percentage of participants in each dose group experiencing ILIs

Time frame:
Day of vaccination through end of study participation (approximately 365 days post-vaccination)
Reported as:
Count of participants · Participants
Number and Percentage of Participants Experiencing Any Influenza-like Illnesses (ILIs)
ParticipantsArm 1, Low DoseArm 2, Medium DoseArm 3, High DoseAny Non-IIV4 DoseArm 4, IIV4
Number and Percentage of Participants Experiencing Any Influenza-like Illnesses (ILIs)13150
PrimaryNumber and Percentage of Participants Experiencing Any Serious Adverse Events (SAEs)

Number and percentage of participants in each dose group experiencing SAEs

Time frame:
Day of vaccination through end of study participation (approximately 365 days post-vaccination)
Reported as:
Count of participants · Participants
Number and Percentage of Participants Experiencing Any Serious Adverse Events (SAEs)
ParticipantsArm 1, Low DoseArm 2, Medium DoseArm 3, High DoseAny Non-IIV4 DoseArm 4, IIV4
Number and Percentage of Participants Experiencing Any Serious Adverse Events (SAEs)00000
PrimaryNumber and Percentage of Participants Experiencing AESIs Corresponding to Myocarditis, Pericarditis, or Myopericarditis

Number and percentage of participants in each dose group experiencing AESIs corresponding to myocarditis, pericarditis, or myopericarditis

Time frame:
Day of vaccination through 56 days post-vaccination
Reported as:
Count of participants · Participants
Number and Percentage of Participants Experiencing AESIs Corresponding to Myocarditis, Pericarditis, or Myopericarditis
ParticipantsArm 1, Low DoseArm 2, Medium DoseArm 3, High DoseAny Non-IIV4 DoseArm 4, IIV4
Myocarditis00000
Pericarditis00000
Myopericarditis00000
PrimaryNumber and Percentage of Participants Experiencing Clinical Laboratory AEs

Number and percentage of participants in each dose group experiencing clinical laboratory AEs

Time frame:
Day of vaccination through 56 days post-vaccination
Reported as:
Count of participants · Participants
Number and Percentage of Participants Experiencing Clinical Laboratory AEs
ParticipantsArm 1, Low DoseArm 2, Medium DoseArm 3, High DoseAny Non-IIV4 DoseArm 4, IIV4
Number and Percentage of Participants Experiencing Clinical Laboratory AEs5512222
SecondaryGeometric Mean Titers (GMT) of Homologous H1-specific Neutralizing Antibodies in a Reporter Microneutralization Assay

Titers for each participant are estimated as the geometric mean of technical replicate results, and the geometric mean is taken again across participants in each dose group at each time point. Results will also be stratified by prior season's receipt of seasonal influenza vaccine within each dose group. Rows are "VRC H1ssF\_3928 mRNA-LNP" and "VRC H1ssF\_3928 mRNA-LNP + Receipt of Prior Season's Influenza Vaccine"

Time frame:
Days 1 (day of vaccination), 8, 15, 29, and 57
Reported as:
Geometric mean · Titer
Geometric Mean Titers (GMT) of Homologous H1-specific Neutralizing Antibodies in a Reporter Microneutralization Assay
TiterLow Dose, 10mcg VRC H1ssF_3928 mRNA-LNPMedium Dose 25mcg VRC H1ssF_3928 mRNA-LNPHigh Dose 50mcg VRC H1ssF_3928 mRNA-LNPIIV4 60 mcg
Baseline - Dose Group87.6 (48.6 to 155.5)78.2 (40.4 to 150.8)151.3 (110.8 to 206.9)105.2 (62.8 to 172.8)
Day 8 - Dose Group99.6 (55.6 to 174.7)124.2 (67.3 to 219.9)199.9 (153.8 to 263.5)111.3 (70.1 to 175.5)
Day 15 - Dose Group123.0 (73.8 to 200.0)144.9 (84.6 to 252.3)236.4 (182.0 to 307.7)106.0 (64.5 to 172.4)
Day 29 - Dose Group125.0 (76.6 to 197.6)140.1 (87.3 to 219.0)217.4 (168.0 to 281.6)114.1 (71.1 to 178.3)
Day 57 - Dose Group113.9 (68.7 to 181.6)88.2 (49.7 to 144.0)196.7 (154.1 to 254.8)122.4 (75.4 to 199.9)
Baseline - Dose Group + Receipt of Prior Season's Influenza Vaccine76.2 (42.0 to 136.7)73.3 (35.3 to 150.4)154.4 (109.5 to 220.5)108.8 (58.0 to 194.7)
Day 8 - Dose Group + Receipt of Prior Season's Influenza Vaccine87.6 (47.6 to 153.3)119.1 (60.2 to 219.1)200.3 (150.4 to 269.6)114.1 (66.8 to 197.9)
Day 15 - Dose Group + Receipt of Prior Season's Influenza Vaccine109.8 (65.5 to 176.1)137.3 (75.8 to 253.9)239.0 (179.1 to 321.7)111.2 (61.4 to 200.2)
Day 29 - Dose Group + Receipt of Prior Season's Influenza Vaccine112.9 (68.9 to 177.8)130.3 (79.3 to 213.9)217.1 (164.1 to 289.8)116.7 (66.5 to 197.9)
Day 57 - Dose Group + Receipt of Prior Season's Influenza Vaccine102.0 (61.7 to 161.1)83.6 (45.5 to 142.5)196.1 (150.1 to 261.2)130.0 (71.6 to 232.7)
Baseline - Dose Group + No Receipt of Prior Season's Influenza Vaccine305.9 (NA to NA)140 (NA to NA)135 (81.9 to 325.5)91.9 (59.1 to 143)
Day 8 - Dose Group + No Receipt of Prior Season's Influenza Vaccine315 (NA to NA)181.1 (NA to NA)197.7 (126.7 to 399.6)100.7 (66.9 to 151.5)
Day 15 - Dose Group + No Receipt of Prior Season's Influenza Vaccine341.5 (NA to NA)236.1 (NA to NA)222.4 (129 to 369.4)87.5 (58.3 to 131.4)
Day 29 - Dose Group + No Receipt of Prior Season's Influenza Vaccine313 (NA to NA)269 (NA to NA)219 (129.3 to 433.7)104.2 (67.4 to 161.2)
Day 57 - Dose Group + No Receipt of Prior Season's Influenza Vaccine308.5 (NA to NA)135 (NA to NA)200 (118.8 to 338)96.2 (63.6 to 145.5)
SecondaryGeometric Mean Fold Rise (GMFR) of Homologous H1-specific Neutralizing Antibodies in a Reporter Microneutralization Assay

Titers for each participant are estimated as the geometric mean of technical replicate results. Fold-rise in titers is calculated as the post-vaccination titer divided by the pre-vaccination titer. The geometric mean of fold-rises is taken again across participants in each group at each time point. Results will also be stratified by prior season's receipt of seasonal influenza vaccine within each dose group.

Time frame:
Days 8, 15, 29, and 57
Reported as:
Geometric mean · fold change
Geometric Mean Fold Rise (GMFR) of Homologous H1-specific Neutralizing Antibodies in a Reporter Microneutralization Assay
fold changeLow Dose, 10mcg VRC H1ssF_3928 mRNA-LNPMedium Dose 25mcg VRC H1ssF_3928 mRNA-LNPHigh Dose 50mcg VRC H1ssF_3928 mRNA-LNPIIV4 60 mcg
Day 8 - Dose Group1.1 (1.0 to 1.2)1.6 (1.3 to 2.0)1.3 (1.2 to 1.5)1.1 (0.9 to 1.3)
Day 15 - Dose Group1.4 (1.2 to 1.7)1.9 (1.5 to 2.3)1.6 (1.4 to 1.8)1.0 (0.9 to 1.1)
Day 29 - Dose Group1.4 (1.2 to 1.8)1.8 (1.4 to 2.3)1.4 (1.3 to 1.6)1.1 (1.0 to 1.2)
Day 57 - Dose Group1.3 (1.1 to 1.6)1.4 (1.2 to 1.6)1.3 (1.2 to 1.4)1.2 (1.0 to 1.3)
Day 8 - Dose Group + Receipt of Prior Season's Influenza Vaccine1.1 (1.0 to 1.3)1.6 (1.3 to 2.1)1.3 (1.1 to 1.5)1.0 (0.9 to 1.3)
Day 15 - Dose Group + Receipt of Prior Season's Influenza Vaccine1.4 (1.2 to 1.7)1.9 (1.5 to 2.4)1.5 (1.4 to 1.8)1.0 (0.9 to 1.1)
Day 29 - Dose Group + Receipt of Prior Season's Influenza Vaccine1.5 (1.2 to 1.8)1.8 (1.4 to 2.3)1.4 (1.3 to 1.6)1.1 (1.0 to 1.2)
Day 57 - Dose Group + Receipt of Prior Season's Influenza Vaccine1.3 (1.1 to 1.6)1.5 (1.3 to 1.7)1.3 (1.1 to 1.4)1.2 (1.0 to 1.4)
Day 8 - Dose Group + No Receipt of Seasonal Influenza Vaccine1.0 (NA to NA)1.3 (NA to NA)1.5 (1.2 to 1.9)1.1 (1.1 to 1.1)
Day 15 - Dose Group + No Receipt of Seasonal Influenza Vaccine1.1 (NA to NA)1.7 (NA to NA)1.6 (1.1 to 2.5)1.0 (0.9 to 1.0)
Day 29 - Dose Group + No Receipt of Seasonal Influenza Vaccine1.0 (NA to NA)1.9 (NA to NA)1.6 (1.3 to 2.0)1.1 (1.1 to 1.1)
Day 57 - Dose Group + No Receipt of Seasonal Influenza Vaccine1.0 (NA to NA)1.0 (NA to NA)1.5 (1.2 to 1.9)1.0 (1.0 to 1.1)
SecondaryGeometric Mean Titers (GMT) of Homologous H1-specific Neutralizing Antibodies in a Viral Microneutralization Assay

Titers for each participant are estimated as the geometric mean of technical replicate results, and the geometric mean is taken again across participants in each dose group at each time point. Results will also be stratified by prior season's receipt of seasonal influenza vaccine within each dose group.

Time frame:
Days 1 (day of vaccination), 8, 15, 29, and 57
Reported as:
Geometric mean · Titer
Geometric Mean Titers (GMT) of Homologous H1-specific Neutralizing Antibodies in a Viral Microneutralization Assay
TiterLow Dose, 10mcg VRC H1ssF_3928 mRNA-LNPMedium Dose 25mcg VRC H1ssF_3928 mRNA-LNPHigh Dose 50mcg VRC H1ssF_3928 mRNA-LNPIIV4 60 mcg
Baseline - Dose Group88.8 (36.1 to 197.0)77.3 (29.3 to 203.9)171.5 (115.1 to 255.5)160.0 (65.0 to 355.1)
Day 8 - Dose Group117.1 (45.9 to 278.6)117.1 (45.9 to 288.4)230.2 (160.0 to 331.3)154.5 (69.6 to 320.0)
Day 15 - Dose Group125.5 (49.2 to 278.6)121.3 (49.2 to 278.6)222.4 (149.3 to 331.3)165.6 (80.0 to 331.3)
Day 29 - Dose Group144.2 (52.8 to 331.3)117.1 (47.6 to 278.6)269.1 (187.0 to 394.0)171.5 (80.0 to 343.0)
Day 57 - Dose Group121.3 (49.2 to 278.6)97.0 (40.0 to 194.0)226.3 (154.5 to 331.3)154.5 (65.0 to 343.0)
Baseline - Dose Group + Receipt of Prior Season's Influenza Vaccine77.0 (29.4 to 179.6)71.3 (25.2 to 209.5)180.8 (122.7 to 266.4)160.0 (51.9 to 433.4)
Day 8 - Dose Group + Receipt of Prior Season's Influenza Vaccine100.8 (37.0 to 254.0)113.1 (40.0 to 296.3)240.5 (163.3 to 354.3)153.2 (56.6 to 364.4)
Day 15 - Dose Group + Receipt of Prior Season's Influenza Vaccine104.8 (40.0 to 244.4)113.1 (41.6 to 285.1)212.8 (135.9 to 333.3)167.1 (67.3 to 364.4)
Day 29 - Dose Group + Receipt of Prior Season's Influenza Vaccine122.2 (43.2 to 285.1)104.8 (40.0 to 254.0)277.4 (180.8 to 417.1)174.5 (73.4 to 415.0)
Day 57 - Dose Group + Receipt of Prior Season's Influenza Vaccine100.8 (37.0 to 235.2)91.1 (35.1 to 198.7)235.7 (153.6 to 354.3)153.2 (51.9 to 415.0)
Baseline - Dose Group + No Receipt of Seasonal Influenza Vaccine320.0 (NA to NA)160.0 (NA to NA)127.0 (40.0 to 640.0)160.0 (80.0 to 320.0)
Day 8 - Dose Group + No Receipt of Seasonal Influenza Vaccine452.5 (NA to NA)160.0 (NA to NA)179.6 (80.0 to 452.5)160.0 (80.0 to 320.0)
Day 15 - Dose Group + No Receipt of Seasonal Influenza Vaccine640.0 (NA to NA)226.3 (NA to NA)285.1 (160.0 to 640.0)160.0 (80.0 to 320.0)
Day 29 - Dose Group + No Receipt of Seasonal Influenza Vaccine640.0 (NA to NA)320.0 (NA to NA)226.3 (113.1 to 640.0)160.0 (80.0 to 320.0)
Day 57 - Dose Group + No Receipt of Seasonal Influenza Vaccine640.0 (NA to NA)160.0 (NA to NA)179.6 (80.0 to 452.5)160.0 (80.0 to 320.0)
SecondaryGeometric Mean Fold Rise (GMFR) of Homologous H1-specific Neutralizing Antibodies in a Viral Microneutralization Assay

Titers for each participant are estimated as the geometric mean of technical replicate results. Fold-rise in titers is calculated as the post-vaccination titer divided by the pre-vaccination titer. The geometric mean of fold-rises is taken again across participants in each group at each time point. Results will also be stratified by prior season's receipt of seasonal influenza vaccine within each dose group.

Time frame:
Days 8, 15, 29, and 57
Reported as:
Geometric mean · fold change
Geometric Mean Fold Rise (GMFR) of Homologous H1-specific Neutralizing Antibodies in a Viral Microneutralization Assay
fold changeLow Dose, 10mcg VRC H1ssF_3928 mRNA-LNPMedium Dose 25mcg VRC H1ssF_3928 mRNA-LNPHigh Dose 50mcg VRC H1ssF_3928 mRNA-LNPIIV4 60 mcg
Day 8 - Dose Group1.3 (1.1 to 1.7)1.5 (1.1 to 2.1)1.3 (1.0 to 1.7)1.0 (0.8 to 1.1)
Day 15 - Dose Group1.4 (1.1 to 1.9)1.6 (1.1 to 2.3)1.3 (1.0 to 1.7)1.0 (0.9 to 1.2)
Day 29 - Dose Group1.6 (1.3 to 2.1)1.5 (1.1 to 2.1)1.6 (1.2 to 2.0)1.1 (0.9 to 1.3)
Day 57 - Dose Group1.4 (1.1 to 1.6)1.7 (1.2 to 2.6)1.3 (1.1 to 1.7)1.0 (0.8 to 1.1)
Day 8 - Dose Group + Receipt of Prior Season's Influenza Vaccine1.3 (1.1 to 1.6)1.6 (1.1 to 2.2)1.3 (1.0 to 1.8)1.0 (0.8 to 1.2)
Day 15 - Dose Group + Receipt of Prior Season's Influenza Vaccine1.4 (1.0 to 1.9)1.6 (1.1 to 2.4)1.2 (0.9 to 1.6)1.0 (0.8 to 1.3)
Day 29 - Dose Group + Receipt of Prior Season's Influenza Vaccine1.6 (1.2 to 2.2)1.5 (1.0 to 2.2)1.5 (1.2 to 2.0)1.1 (0.9 to 1.4)
Day 57 - Dose Group + Receipt of Prior Season's Influenza Vaccine1.3 (1.1 to 1.6)1.8 (1.2 to 2.8)1.3 (1.1 to 1.6)1.0 (0.8 to 1.1)
Day 8 - Dose Group + No Receipt of Seasonal Influenza Vaccine1.4 (NA to NA)1.0 (NA to NA)1.4 (0.7 to 2.0)1.0 (1.0 to 1.0)
Day 15 - Dose Group + No Receipt of Seasonal Influenza Vaccine2.0 (NA to NA)1.4 (NA to NA)2.2 (1.0 to 5.7)1.0 (1.0 to 1.0)
Day 29 - Dose Group + No Receipt of Seasonal Influenza Vaccine2.0 (NA to NA)2.0 (NA to NA)1.8 (1.0 to 4.0)1.0 (1.0 to 1.0)
Day 57 - Dose Group + No Receipt of Seasonal Influenza Vaccine2.0 (NA to NA)1.0 (NA to NA)1.4 (0.7 to 4.0)1.0 (1.0 to 1.0)
SecondaryGeometric Mean Titers (GMT) of Anti-stalk Serum Antibodies, Measured by Enzyme Linked Immunosorbent Assay (ELISA)

The geometric mean of titers is taken again across participants in each dose group at each time point. Results will also be stratified by prior season's receipt of seasonal influenza vaccine within each dose group.

Time frame:
Days 1 (day of vaccination), 8, 15, 29, and 57
Reported as:
Geometric mean · Titer
Geometric Mean Titers (GMT) of Anti-stalk Serum Antibodies, Measured by Enzyme Linked Immunosorbent Assay (ELISA)
TiterLow Dose, 10mcg VRC H1ssF_3928 mRNA-LNPMedium Dose 25mcg VRC H1ssF_3928 mRNA-LNPHigh Dose 50mcg VRC H1ssF_3928 mRNA-LNPIIV4 60 mcg
Baseline - Dose Group32310.5 (22476.5 to 47917.6)21910.1 (12679.2 to 33832.9)43179.1 (31338.7 to 59574.7)27409.8 (21001.0 to 34882.0)
Day 8 - Dose Group110982.1 (56067.9 to 215643.8)162149.9 (88679.0 to 300949.9)299857.5 (198284.8 to 469239.0)46133.1 (32557.7 to 68073.8)
Day 15 - Dose Group300406.0 (188490.5 to 479337.5)351954.9 (217256.6 to 533957.5)967717.5 (575841.6 to 1653650.2)49693.2 (36201.4 to 67221.9)
Day 29 - Dose Group252954.3 (154658.1 to 400507.3)282368.3 (184446.3 to 401455.1)599513.3 (419485.4 to 850398.6)51515.1 (39736.0 to 67561.3)
Day 57 - Dose Group230351.2 (150357.8 to 342113.8)219708.4 (133947.6 to 328952.9)496554.5 (356138.3 to 694997.2)41466.5 (31949.4 to 53741.9)
Baseline - Dose Group + Receipt of Prior Season's Influenza Vaccine35718.4 (25062.8 to 52200.2)20762.1 (11567.3 to 34010.5)48734.6 (34773.3 to 68479.6)27638.3 (20061.6 to 36401.6)
Day 8 - Dose Group + Receipt of Prior Season's Influenza Vaccine137098.6 (75401.8 to 253957.5)186797.4 (101057.6 to 349451.5)286800.5 (182406.6 to 478426.3)36667.9 (28118.5 to 49008.2)
Day 15 - Dose Group + Receipt of Prior Season's Influenza Vaccine311658.1 (186972.3 to 517516.4)341659.4 (197931.1 to 541900.8)910946.4 (511455.4 to 1674366.8)42538.3 (31316.9 to 56593.7)
Day 29 - Dose Group + Receipt of Prior Season's Influenza Vaccine278050.6 (168415.1 to 441979.2)270864.2 (171191.6 to 401586.7)600226.6 (400234.0 to 892057.4)45154.8 (35953.5 to 54337.9)
Day 57 - Dose Group + Receipt of Prior Season's Influenza Vaccine255801.1 (165884.8 to 372010.5)210266.0 (123422.2 to 331887.5)483327.8 (334300.7 to 709989.0)35724.9 (28393.5 to 42485.4)
Baseline - Dose Group + No Receipt of Seasonal Influenza Vaccine13104.0 (NA to NA)35562.6 (NA to NA)21747.7 (13350.7 to 31668.6)26514.9 (18375.9 to 38258.8)
Day 8 - Dose Group + No Receipt of Seasonal Influenza Vaccine16566.6 (NA to NA)45376.3 (NA to NA)385904.7 (189625.1 to 551293.3)115590.0 (82913.7 to 161143.9)
Day 15 - Dose Group + No Receipt of Seasonal Influenza Vaccine215764.8 (NA to NA)459759.4 (NA to NA)1363110.8 (378750.2 to 4772553.5)92547.4 (72857.6 to 117558.3)
Day 29 - Dose Group + No Receipt of Seasonal Influenza Vaccine107970.7 (NA to NA)410576.5 (NA to NA)595487.5 (285879.7 to 889748.5)87268.4 (60085.9 to 126748.0)
Day 57 - Dose Group + No Receipt of Seasonal Influenza Vaccine89698.1 (NA to NA)312224.2 (NA to NA)578641.2 (243490.3 to 928806.1)75266.3 (57870.1 to 97891.8)
SecondaryGeometric Mean Fold Rise (GMFR) of Anti-stalk Serum Antibodies, Measured by Enzyme Linked Immunosorbent Assay (ELISA)

Fold-rise in titers is calculated as the post-vaccination titer divided by the pre-vaccination titer. The geometric mean of fold-rises is taken again across participants in each group at each time point. Results will also be stratified by prior season's receipt of seasonal influenza vaccine within each dose group.

Time frame:
Days 8, 15, 29, and 57
Reported as:
Geometric mean · fold change
Geometric Mean Fold Rise (GMFR) of Anti-stalk Serum Antibodies, Measured by Enzyme Linked Immunosorbent Assay (ELISA)
fold changeLow Dose, 10mcg VRC H1ssF_3928 mRNA-LNPMedium Dose 25mcg VRC H1ssF_3928 mRNA-LNPHigh Dose 50mcg VRC H1ssF_3928 mRNA-LNPIIV4 60 mcg
Day 8 - Dose Group3.4 (1.9 to 6.6)7.4 (4.2 to 12.5)6.9 (4.2 to 11.1)1.7 (1.2 to 2.6)
Day 15 - Dose Group9.3 (6.0 to 13.9)16.1 (10.2 to 23.8)22.4 (13.2 to 38.0)1.8 (1.2 to 2.8)
Day 29 - Dose Group7.8 (5.0 to 11.8)12.9 (9.2 to 18.0)13.9 (9.9 to 19.1)1.9 (1.5 to 2.6)
Day 57 - Dose Group7.1 (4.8 to 10.1)11.1 (7.3 to 16.4)11.5 (8.4 to 15.7)1.5 (1.1 to 2.2)
Day 8 - Dose Group + Receipt of Prior Season's Influenza Vaccine3.8 (2.1 to 7.4)9.0 (5.5 to 13.9)5.9 (3.4 to 10.0)1.3 (1.0 to 1.7)
Day 15 - Dose Group + Receipt of Prior Season's Influenza Vaccine8.7 (5.4 to 13.5)16.5 (9.9 to 25.2)18.7 (10.7 to 33.0)1.5 (1.1 to 2.4)
Day 29 - Dose Group + Receipt of Prior Season's Influenza Vaccine7.8 (4.8 to 12.3)13.0 (8.9 to 18.6)12.3 (8.6 to 17.3)1.6 (1.4 to 2.0)
Day 57 - Dose Group + Receipt of Prior Season's Influenza Vaccine7.2 (4.6 to 10.6)11.5 (7.1 to 17.6)9.9 (7.2 to 13.9)1.3 (1.0 to 1.7)
Day 8 - Dose Group + No Receipt of Seasonal Influenza Vaccine1.3 (NA to NA)1.3 (NA to NA)17.7 (14.2 to 22.7)4.4 (2.2 to 8.8)
Day 15 - Dose Group + No Receipt of Seasonal Influenza Vaccine16.5 (NA to NA)12.9 (NA to NA)62.7 (28.4 to 150.7)3.5 (1.9 to 6.4)
Day 29 - Dose Group + No Receipt of Seasonal Influenza Vaccine8.2 (NA to NA)11.5 (NA to NA)27.4 (21.4 to 36.6)3.3 (1.6 to 6.9)
Day 57 - Dose Group + No Receipt of Seasonal Influenza Vaccine6.8 (NA to NA)8.8 (NA to NA)26.6 (18.2 to 38.2)2.8 (1.5 to 5.3)

Adverse events

Collected over Solicited AEs were collected through 13 days post-vaccination. Serious adverse events were collected through end of study participation, approximately 365 days post-vaccination. All other unsolicited AEs were collected through 28 days post-vaccination.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Low Dose, 10mcg VRC H1ssF_3928 mRNA-LNP0/10 (0%)0/10 (0%)10/10 (100%)
Medium Dose 25mcg VRC H1ssF_3928 mRNA-LNP0/10 (0%)0/10 (0%)10/10 (100%)
High Dose 50mcg VRC H1ssF_3928 mRNA-LNP0/20 (0%)0/20 (0%)20/20 (100%)
Any Non-IIV4 Dose0/40 (0%)0/40 (0%)40/40 (100%)
IIV4 60 mcg0/10 (0%)0/10 (0%)9/10 (90%)
Most frequent other events
Showing 10 of 58
Most frequent other events
EventLow Dose, 10mcg VRC H1ssF_3928 mRNA-LNPMedium Dose 25mcg VRC H1ssF_3928 mRNA-LNPHigh Dose 50mcg VRC H1ssF_3928 mRNA-LNPAny Non-IIV4 DoseIIV4 60 mcg
Injection site pain (Local)General disorders10/1010/1019/2039/406/10
Fatigue (Systemic)General disorders6/106/1011/2023/402/10
Headache (Systemic)Nervous system disorders3/105/106/2014/403/10
Upper respiratory tract infectionInfections and infestations1/103/102/206/400/10
Haemoglobin decreasedInvestigations3/101/103/207/400/10
Myalgia (Systemic)Musculoskeletal and connective tissue disorders2/103/102/207/400/10
Diarrhoea (Systemic)Gastrointestinal disorders2/101/101/204/400/10
Nausea (Systemic)Gastrointestinal disorders1/101/103/205/400/10
Chills (Systemic)General disorders0/101/103/204/401/10
Neutrophil count decreasedInvestigations0/100/103/203/401/10

Baseline characteristics

All participants

Age, Continuous
Age, Continuous(years)Arm 1, Low DoseArm 2, Medium DoseArm 3, High DoseArm 4, IIV4Total
Mean33 ± 6.431.2 ± 6.836.3 ± 832.2 ± 6.133.8 ± 7.2
Sex: Female, Male
Sex: Female, Male(Participants)Arm 1, Low DoseArm 2, Medium DoseArm 3, High DoseArm 4, IIV4Total
Female668525
Male4412525
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm 1, Low DoseArm 2, Medium DoseArm 3, High DoseArm 4, IIV4Total
American Indian or Alaska Native00000
Asian00101
Native Hawaiian or Other Pacific Islander00000
Black or African American00011
White10919745
More than one race01012
Unknown or Not Reported00011
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm 1, Low DoseArm 2, Medium DoseArm 3, High DoseArm 4, IIV4Total
Hispanic or Latino10124
Not Hispanic or Latino91019846
Unknown or Not Reported00000
Receipt of prior season's influenza vaccine
Receipt of prior season's influenza vaccine(Participants)Arm 1, Low DoseArm 2, Medium DoseArm 3, High DoseArm 4, IIV4Total
Count of participants9917843
08

Study locations

1 site
  • Duke Vaccine and Trials Unit
    Durham, North Carolina 27704, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2023 to primary completion in Oct 2025, 29 months.

Results were first posted in Nov 2026, 1 year 1 month after primary completion.

Of 54 non-industry phase 1 interventional studies under Influenza, Human, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 31. This study's 29 months is above that.

Counting every sponsor, half of 148 studies reached it within 11 months; a quarter within 4 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2023
First posted
Mar 6, 2023
StartActual
Apr 5, 2023
Primary completionActual
Oct 3, 2025
CompletionActual
Oct 3, 2025
Results first posted
Nov 19, 2026
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 19, 2026
Interventions
Arm changed Arm 5, IIV4→Arm 4, IIV4. Arms removed: Arm 4, Optimal Dose
Nov 19, 2026
Primary outcomes
4 edited, 4 added, 5 removed
What changed in the outcomes
  • EditedOccurrenceNumber and Percentage of adverse events of special interest (AESIs) correspondingParticipants Experiencing AESIs Corresponding to myocarditisMyocarditis, pericarditisPericarditis, or myopericarditis with VRC H1ssF_3928 mRNA-LNP vaccineMyopericarditisTime frame: Day 1 through Day 57 → Day of vaccination through 56 days post-vaccination
  • EditedOccurrenceNumber and Percentage of any influenzaParticipants Experiencing Any Influenza-like illnessesIllnesses (ILIs) with VRC H1ssF_3928 mRNA-LNP vaccine.Time frame: Day 1 through Day 366 → Day of vaccination through end of study participation (approximately 365 days post-vaccination)
  • EditedOccurrenceNumber and Percentage of any newParticipants Experiencing Any New-onset chronic medical conditionsChronic Medical Conditions (NOCMCs) with VRC H1ssF_3928 mRNA-LNP vaccine.Time frame: Day 1 through Day 366 → Day of vaccination through end of study participation (approximately 365 days post-vaccination)
  • EditedOccurrenceNumber and Percentage of any serious adverse eventsParticipants Experiencing Any Serious Adverse Events (SAEs) with VRC H1ssF_3928 mRNA-LNP vaccine.Time frame: Day 1 through Day 366 → Day of vaccination through end of study participation (approximately 365 days post-vaccination)
  • AddedNumber and Percentage of Participants Experiencing Solicited Local and Systemic Reactogenicity Adverse Events (AEs)Time frame: Day of vaccination through 13 days post-vaccination
  • AddedNumber and Percentage of Participants Experiencing Any Unsolicited AEsTime frame: Day of vaccination through 28 days post-vaccination
  • AddedNumber and Percentage of Participants Experiencing Any Adverse Events of Special Interest (AESIs) Corresponding to Grade 2 or Greater Decrease in Lymphocyte or Neutrophil CountTime frame: Day of vaccination through end of study participation (approximately 365 days post-vaccination)
  • AddedNumber and Percentage of Participants Experiencing Clinical Laboratory AEsTime frame: Day of vaccination through 56 days post-vaccination
  • RemovedOccurrence of any adverse events of special interest (AESIs) with VRC H1ssF_3928 mRNA-LNP vaccine.Time frame: Day 1 through Day 366
  • RemovedOccurrence of any unsolicited adverse events (AEs) with VRC H1ssF_3928 mRNA-LNP vaccine.Time frame: Day 1 through Day 28
  • RemovedOccurrence of clinical laboratory adverse events (AEs) with VRC H1ssF_3928 mRNA-LNP vaccine.Time frame: Day 1 through Day 57
  • RemovedOccurrence of medically attended adverse events (MAAEs) with VRC H1ssF_3928 mRNA-LNP vaccine.Time frame: Day 1 through Day 366
  • RemovedOccurrence of solicited reactogenicity adverse events (AEs) with VRC H1ssF_3928 mRNA-LNP vaccine.Time frame: Day 1 through Day 14
Nov 19, 2026
Secondary outcomes
6 edited
What changed in the outcomes
  • EditedGeometric mean fold riseMean Fold Rise (GMFR) of antiHomologous H1-stalk serum antibodies measured by enzyme linked immunosorbent assay (ELISA).specific Neutralizing Antibodies in a Reporter Microneutralization AssayTime frame: Day 1 through Day 57 → Days 8, 15, 29, and 57
  • EditedGeometric mean fold riseMean Titers (GMFRGMT) of homologousHomologous H1-specific neutralizing antibodiesNeutralizing Antibodies in a reporter microneutralization assay.Reporter Microneutralization AssayTime frame: Day 1 through Day 57 → Days 1 (day of vaccination), 8, 15, 29, and 57
  • EditedGeometric mean fold riseMean Titers (GMFRGMT) of homologousHomologous H1-specific neutralizing antibodiesNeutralizing Antibodies in a viral microneutralization assay.Viral Microneutralization AssayTime frame: Day 1 through Day 57 → Days 1 (day of vaccination), 8, 15, 29, and 57
  • EditedGeometric mean titersMean Fold Rise (GMTGMFR) of homologousHomologous H1-specific neutralizing antibodiesNeutralizing Antibodies in a reporter microneutralization assay.Viral Microneutralization AssayTime frame: Day 1 through Day 57 → Days 8, 15, 29, and 57
  • EditedGeometric mean titersMean Titers (GMT) of antiAnti-stalk serum antibodies measuredSerum Antibodies, Measured by enzyme linked immunosorbent assayEnzyme Linked Immunosorbent Assay (ELISA).Time frame: Day 1 through Day 57 → Days 1 (day of vaccination), 8, 15, 29, and 57
  • ChangedBefore Geometric mean titers (GMT) Of homologous H1-specific neutralizing antibodies in a viral microneutralization assay.Now Geometric Mean Fold Rise (GMFR) of Anti-stalk Serum Antibodies, Measured by Enzyme Linked Immunosorbent Assay (ELISA)Time frame: Day 1 through Day 57 → Days 8, 15, 29, and 57
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Results posted
    Primary outcomes 4 edited, 4 added, 5 removed
    What changed in the outcomes
    • EditedOccurrenceNumber and Percentage of adverse events of special interest (AESIs) correspondingParticipants Experiencing AESIs Corresponding to myocarditisMyocarditis, pericarditisPericarditis, or myopericarditis with VRC H1ssF_3928 mRNA-LNP vaccineMyopericarditisTime frame: Day 1 through Day 57 → Day of vaccination through 56 days post-vaccination
    • EditedOccurrenceNumber and Percentage of any influenzaParticipants Experiencing Any Influenza-like illnessesIllnesses (ILIs) with VRC H1ssF_3928 mRNA-LNP vaccine.Time frame: Day 1 through Day 366 → Day of vaccination through end of study participation (approximately 365 days post-vaccination)
    • EditedOccurrenceNumber and Percentage of any newParticipants Experiencing Any New-onset chronic medical conditionsChronic Medical Conditions (NOCMCs) with VRC H1ssF_3928 mRNA-LNP vaccine.Time frame: Day 1 through Day 366 → Day of vaccination through end of study participation (approximately 365 days post-vaccination)
    • EditedOccurrenceNumber and Percentage of any serious adverse eventsParticipants Experiencing Any Serious Adverse Events (SAEs) with VRC H1ssF_3928 mRNA-LNP vaccine.Time frame: Day 1 through Day 366 → Day of vaccination through end of study participation (approximately 365 days post-vaccination)
    • AddedNumber and Percentage of Participants Experiencing Solicited Local and Systemic Reactogenicity Adverse Events (AEs)Time frame: Day of vaccination through 13 days post-vaccination
    • AddedNumber and Percentage of Participants Experiencing Any Unsolicited AEsTime frame: Day of vaccination through 28 days post-vaccination
    • AddedNumber and Percentage of Participants Experiencing Any Adverse Events of Special Interest (AESIs) Corresponding to Grade 2 or Greater Decrease in Lymphocyte or Neutrophil CountTime frame: Day of vaccination through end of study participation (approximately 365 days post-vaccination)
    • AddedNumber and Percentage of Participants Experiencing Clinical Laboratory AEsTime frame: Day of vaccination through 56 days post-vaccination
    • RemovedOccurrence of any adverse events of special interest (AESIs) with VRC H1ssF_3928 mRNA-LNP vaccine.Time frame: Day 1 through Day 366
    • RemovedOccurrence of any unsolicited adverse events (AEs) with VRC H1ssF_3928 mRNA-LNP vaccine.Time frame: Day 1 through Day 28
    • RemovedOccurrence of clinical laboratory adverse events (AEs) with VRC H1ssF_3928 mRNA-LNP vaccine.Time frame: Day 1 through Day 57
    • RemovedOccurrence of medically attended adverse events (MAAEs) with VRC H1ssF_3928 mRNA-LNP vaccine.Time frame: Day 1 through Day 366
    • RemovedOccurrence of solicited reactogenicity adverse events (AEs) with VRC H1ssF_3928 mRNA-LNP vaccine.Time frame: Day 1 through Day 14
    Secondary outcomes 6 edited
    What changed in the outcomes
    • EditedGeometric mean fold riseMean Fold Rise (GMFR) of antiHomologous H1-stalk serum antibodies measured by enzyme linked immunosorbent assay (ELISA).specific Neutralizing Antibodies in a Reporter Microneutralization AssayTime frame: Day 1 through Day 57 → Days 8, 15, 29, and 57
    • EditedGeometric mean fold riseMean Titers (GMFRGMT) of homologousHomologous H1-specific neutralizing antibodiesNeutralizing Antibodies in a reporter microneutralization assay.Reporter Microneutralization AssayTime frame: Day 1 through Day 57 → Days 1 (day of vaccination), 8, 15, 29, and 57
    • EditedGeometric mean fold riseMean Titers (GMFRGMT) of homologousHomologous H1-specific neutralizing antibodiesNeutralizing Antibodies in a viral microneutralization assay.Viral Microneutralization AssayTime frame: Day 1 through Day 57 → Days 1 (day of vaccination), 8, 15, 29, and 57
    • EditedGeometric mean titersMean Fold Rise (GMTGMFR) of homologousHomologous H1-specific neutralizing antibodiesNeutralizing Antibodies in a reporter microneutralization assay.Viral Microneutralization AssayTime frame: Day 1 through Day 57 → Days 8, 15, 29, and 57
    • EditedGeometric mean titersMean Titers (GMT) of antiAnti-stalk serum antibodies measuredSerum Antibodies, Measured by enzyme linked immunosorbent assayEnzyme Linked Immunosorbent Assay (ELISA).Time frame: Day 1 through Day 57 → Days 1 (day of vaccination), 8, 15, 29, and 57
    • ChangedBefore Geometric mean titers (GMT) Of homologous H1-specific neutralizing antibodies in a viral microneutralization assay.Now Geometric Mean Fold Rise (GMFR) of Anti-stalk Serum Antibodies, Measured by Enzyme Linked Immunosorbent Assay (ELISA)Time frame: Day 1 through Day 57 → Days 8, 15, 29, and 57
    Interventions Arm changed Arm 5, IIV4→Arm 4, IIV4. Arms removed: Arm 4, Optimal Dose
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05755620
Responsible party
Sponsor
First posted
Mar 6, 2023
Start date
Apr 5, 2023
Primary completion
Oct 3, 2025
Completion
Oct 3, 2025
Results posted
Nov 19, 2026
Last update
Nov 19, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion